Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 877

Results For "LA"

8967 News Found

Abbott's Freestyle Libre 2 Ios App Cleared In U.S
Drug Approval | August 03, 2021

Abbott's Freestyle Libre 2 Ios App Cleared In U.S

FreeStyle Libre 2 iOS app is the only sensor-based glucose monitoring app that allows users to check their glucose with a compatible iPhone every minute with optional real-time glucose alarms


Meddo acquires Doxper in a cash and stock deal
Healthcare | August 03, 2021

Meddo acquires Doxper in a cash and stock deal

This deal makes Meddo, one of the largest health-tech players in India


Drug exports grow on the back of govt support
Policy | August 03, 2021

Drug exports grow on the back of govt support

Drug formulations and biologics make impressive gains


Nureca Ltd PAT at Rs 36.19 crore in Q1FY22
Healthcare | August 03, 2021

Nureca Ltd PAT at Rs 36.19 crore in Q1FY22

Nureca Ltd has reported financial results for the period ended June 30, 2021.


NPPA monitors and caps prices of essential drugs: Mandaviya
Policy | August 03, 2021

NPPA monitors and caps prices of essential drugs: Mandaviya

NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level


NPPA caps prices on five medical devices effective July 20th 2021
Policy | August 03, 2021

NPPA caps prices on five medical devices effective July 20th 2021

The highest reduction in prices for Pulse Oximeters, Blood Pressure Monitoring Machine and Nebulizer has been reported by importers


API exports surpass imports by value in 2020-21
Policy | August 03, 2021

API exports surpass imports by value in 2020-21

The govt has rolled out three schemes for promoting the manufacture of API


AYUSH 64 effective in mild and moderate COVID 19
Drug Approval | August 03, 2021

AYUSH 64 effective in mild and moderate COVID 19

It works as an adjunct to standard care based on robust clinical trials


Granules India earmarks Rs 400 crore as Capex for FY 22
News | August 02, 2021

Granules India earmarks Rs 400 crore as Capex for FY 22

The company has an outlay of Rs 120-140 crore as R & D expense for FY 22


Glenmark signs agreement with SaNOtize to manufacture NONS
News | August 02, 2021

Glenmark signs agreement with SaNOtize to manufacture NONS

The Phase III clinical trial for NONS is expected to be completed by Q4 2021.